FDA WARNING_LETTER - Forrest Media Incorporated

The FDA issued a Warning Letter after reviewing several websites, including approved-swiss-meds.com and swissmeds.com, which were found to be offering unapproved and misbranded drugs for sale. The products, such as "Acomplia," "Rimonabant," "Viagra," "Cialis," and "Prozac," are considered drugs under section 201(g) of the Federal Food, Drug, and Cosmetic Act. The firm is in violation for selling unapproved new drugs, specifically "Acomplia" and "Rimonabant," which lack FDA-approved applications, violating sections 301(d) and 505(a) of the Act. Rimonabant was previously rejected by the FDA due to significant safety concerns. Additionally, the firm's websites offer prescription drugs like "Viagra," "Cialis," and "Prozac" without requiring a valid prescription, rendering them misbranded under section 503(b)(1) and violating sections 301(a), 301(b), and 301(k). Furthermore, the websites falsely claim compliance with U.S. law, leading to misbranding under section 502(a) due to false and misleading labeling, violating section 301(a). The FDA emphasized the inherent risks of unapproved drugs from unregulated sources, which lack safety and effectiveness assurances. The firm is required to immediately cease marketing violative products and respond in writing within 15 working days with corrective actions taken or planned to prevent recurrence. Failure to comply may result in regulatory actions such as seizure or injunction.